Quarterly ResultAug 5, 2026, 07:08 AM
Seres Therapeutics Q2 2026 Net Income $4.6M; Reduces Facility Costs
AI Summary
Seres Therapeutics reported a net income of $4.6 million for the second quarter of 2026, a significant improvement from a net loss of $19.9 million in the prior year, primarily driven by a $25 million gain from a Milestone Termination Payment from Nestlé. The company also announced positive topline results from an investigator-sponsored trial of SER-155 in immune checkpoint inhibitor-related enterocolitis (irEC), with 80% of participants achieving an immunosuppressive-free clinical response. Additionally, Seres is taking further actions to reduce ongoing facility costs, including terminating a lease, and expects to fund operations through Q1 2027.
Key Highlights
- Reported net income of $4.6 million for Q2 2026, compared to a net loss of $19.9 million in Q2 2025.
- Recognized a $25 million gain from Milestone Termination Payment from Nestlé Health Science.
- Research and development expenses decreased to $9.1 million in Q2 2026 from $12.9 million in Q2 2025.
- General and administrative expenses decreased to $7.1 million in Q2 2026 from $10.3 million in Q2 2025.
- 80% of SER-155 recipients achieved immunosuppressive-free clinical response at day 15 for irEC.
- Agreed to terminate the lease for 200 Sidney Street, reducing future facility-related cash costs.
- Cash and cash equivalents totaled $15.6 million as of June 30, 2026.
- Expects to fund operations through Q1 2027 with current resources and expected Nestlé payment.
Price Impact
More from MCRB